{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:17:56Z","timestamp":1779383876106,"version":"3.53.1"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Extracorporeal membrane oxygenation (ECMO) systems for permanent respiratory support are currently under development as an alternative to lung transplantation. Direct oral anticoagulants are a promising alternative to heparin due to their oral administration and predictable pharmacology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>The efficacy of rivaroxaban for artificial surface anticoagulation was evaluated using 3 studies that determined (1) the pharmacological behavior of 0.25, 0.5, and 1\u2009mg\/kg doses of rivaroxaban in sheep; (2) the artificial surface anticoagulation efficacy of these 3 doses compared with heparin in a short-term mini-ECMO model; and (3) the efficacy of the optimal dose from study 2 with simulated oral pharmacokinetics in an extended-duration mini-ECMO model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      Study 1 found that sheep have a higher volume of distribution (2.2\u2005\u00b1\u20050.4\u2009L\/kg) and a shorter half-life (1.4\u2005\u00b1\u20050.1\u2009h) for rivaroxaban than humans but a similar linear relationship between prothrombin time and rivaroxaban plasma concentration. In study 2, device survival time in the heparin group (57.5\u2005\u00b1\u200513.0\u2009min) was most similar to the 0.5\u2009mg\/kg rivaroxaban group (51.3\u2005\u00b1\u20058.8\u2009min;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.287). This dose was selected for study 3, and no difference was found in device survival time between heparin (6.3\u2005\u00b1\u20051.3\u2009h) and the 0.5\u2009mg\/kg rivaroxaban infusion (6.3\u2005\u00b1\u20051.6\u2009h;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.837). Furthermore, the calculated rivaroxaban exposure was similar to the clinically approved oral rivaroxaban doses (24-h area under the plasma concentration curve\u2005=\u20052074 \u00b5g h\/L).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>These results demonstrate that rivaroxaban has artificial surface anticoagulation efficacy similar to that of heparin at dosages that are feasible for oral administration in humans. Future studies will evaluate rivaroxaban anticoagulation using a 10-d full-scale ovine ECMO model.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005617","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:00:32Z","timestamp":1770613232000},"page":"e836-e846","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Development of an Oral Anticoagulation Strategy for Permanent Artificial Lung Support"],"prefix":"10.1097","volume":"110","author":[{"given":"Yeahwa","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA."},{"name":"Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA."},{"name":"Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Nasim","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA."},{"name":"Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Akhavanmalayeri","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Scala","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick I.","family":"Iyasele","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly R.","family":"Strong","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suji","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail E.","family":"Gredell","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith E.","family":"Cook","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"R2-20260521","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1513\/pats.200701-003FM","article-title":"Exacerbations of chronic obstructive pulmonary disease.","volume":"4","author":"Anzueto","year":"2007","journal-title":"Proc Am Thorac Soc"},{"key":"R3-20260521","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1016\/j.ajt.2024.01.017","article-title":"OPTN\/SRTR 2022 annual data report: lung.","volume":"24","author":"Valapour","year":"2024","journal-title":"Am J Transplant"},{"key":"R4-20260521","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/TP.0000000000003481","article-title":"Month-long respiratory support by a wearable pumping artificial lung in an ovine model.","volume":"105","author":"Orizondo","year":"2021","journal-title":"Transplantation"},{"key":"R5-20260521","first-page":"100093","article-title":"Development of an ambulatory extracorporeal membrane oxygenation system: from concept to clinical use.","volume":"10","author":"Han","year":"2022","journal-title":"Appl Eng Sci"},{"key":"R6-20260521","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.athoracsur.2020.01.039","article-title":"Safety and efficacy of a novel pneumatically driven extracorporeal membrane oxygenation device.","volume":"109","author":"Karagiannidis","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"R7-20260521","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/MAT.0000000000002030","article-title":"Pilot testing of a lightweight, pulmonary assist system in an ambulatory sheep model of destination therapy respiratory support.","volume":"70","author":"Roberts","year":"2024","journal-title":"ASAIO J"},{"key":"R8-20260521","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/MAT.0000000000002227","article-title":"Hemocompatibility evaluation of a novel ambulatory pulmonary assist system using a lightweight axial-flow pump.","volume":"70","author":"Hong","year":"2024","journal-title":"ASAIO J"},{"key":"R9-20260521","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/TP.0000000000005165","article-title":"Five-day wearable respiratory support with a novel ambulatory pulmonary assist system in an awake ovine model.","volume":"109","author":"Hong","year":"2024","journal-title":"Transplantation"},{"key":"R10-20260521","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MOT.0000000000001163","article-title":"Progress towards permanent respiratory support.","volume":"29","author":"Shin","year":"2024","journal-title":"Curr Opin Organ Transplant"},{"key":"R11-20260521","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.21037\/jtd.2017.06.75","article-title":"Neurological complications during veno-venous extracorporeal membrane oxygenation.","volume":"9","author":"Hirose","year":"2017","journal-title":"J Thorac Dis"},{"key":"R12-20260521","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.tmrv.2014.12.001","article-title":"Extracorporeal membrane oxygenation-hemostatic complications.","volume":"29","author":"Murphy","year":"2015","journal-title":"Transfus Med Rev"},{"key":"R13-20260521","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.thromres.2022.02.015","article-title":"Venous thromboembolic events in the setting of extracorporeal membrane oxygenation support in adults: a systematic review.","volume":"212","author":"Abruzzo","year":"2022","journal-title":"Thromb Res"},{"key":"R14-20260521","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/MAT.0000000000001605","article-title":"Thrombosis in extracorporeal membrane oxygenation (ECMO) circuits.","volume":"68","author":"Figueroa Villalba","journal-title":"ASAIO J"},{"key":"R15-20260521","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.thromres.2022.02.011","article-title":"Coagulation activation during extracorporeal membrane oxygenation (ECMO).","volume":"211","author":"Chandler","year":"2022","journal-title":"Thromb Res"},{"key":"R16-20260521","doi-asserted-by":"crossref","first-page":"102829","DOI":"10.1016\/j.iccn.2020.102829","article-title":"ECMO survivors\u2019 quality of life and needs after discharge: a descriptive, comparative cross-sectional pilot study.","volume":"59","author":"Tiedebohl","year":"2020","journal-title":"Intensive Crit Care Nurs"},{"key":"R17-20260521","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00228-023-03568-3","article-title":"Anticoagulants in adult extracorporeal membrane oxygenation: alternatives to standardized anticoagulation with unfractionated heparin.","volume":"79","author":"Tang","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"R18-20260521","doi-asserted-by":"crossref","first-page":"e13530","DOI":"10.1016\/j.heliyon.2023.e13530","article-title":"Superiority of bivalirudin over heparin anticoagulation therapy for extracorporeal membrane oxygenation? Too early to draw conclusions.","volume":"9","author":"Gu","year":"2023","journal-title":"Heliyon"},{"key":"R19-20260521","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1472-8206.2011.00981.x","article-title":"Pharmacodynamic and pharmacokinetic basics of rivaroxaban.","volume":"26","author":"Kreutz","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"R20-20260521","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R21-20260521","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"R22-20260521","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5414\/CP201812","article-title":"The effect of food on the absorption and pharmacokinetics of rivaroxaban.","volume":"51","author":"Stampfuss","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R23-20260521","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/psp4.12288","article-title":"Integrated population pharmacokinetic analysis of rivaroxaban across multiple patient populations.","volume":"7","author":"Willmann","year":"2018","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"R24-20260521","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ejcts\/ezt545","article-title":"Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model.","volume":"45","author":"Greiten","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"R25-20260521","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s11748-020-01371-w","article-title":"Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices.","volume":"68","author":"Parikh","year":"2020","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"R26-20260521","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cardfail.2023.10.473","article-title":"Design and rationale for the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study.","volume":"30","author":"Dimond","year":"2024","journal-title":"J Card Fail"},{"key":"R27-20260521","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1076029616675968","article-title":"Estimation of rivaroxaban plasma concentrations in the perioperative setting in patients with or without heparin bridging.","volume":"24","author":"Lessire","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"R28-20260521","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s42466-021-00105-4","article-title":"Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban.","volume":"3","author":"Hartig","year":"2021","journal-title":"Neurol Res Pract"},{"key":"R29-20260521","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchromb.2008.07.015","article-title":"Determination of rivaroxaban\u2014a novel, oral, direct Factor Xa inhibitor\u2014in human plasma by high-performance liquid chromatography-tandem mass spectrometry.","volume":"872","author":"Rohde","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R30-20260521","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1160\/TH13-04-0274","article-title":"Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS\/MS for the therapeutic monitoring of patients treated with rivaroxaban.","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb Haemost"},{"key":"R31-20260521","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.actbio.2019.04.004","article-title":"72-Hour in vivo evaluation of nitric oxide generating artificial lung gas exchange fibers in sheep.","volume":"90","author":"Lai","year":"2019","journal-title":"Acta Biomater"},{"key":"R32-20260521","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/01.mat.0000169707.72242.8f","article-title":"Hemodynamic and gas transfer properties of a compliant thoracic artificial lung.","volume":"51","author":"Cook","year":"2005","journal-title":"ASAIO J"},{"key":"R33-20260521","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00134-011-2439-2","article-title":"Contemporary extracorporeal membrane oxygenation for adult respiratory failure: life support in the new era.","volume":"38","author":"MacLaren","year":"2012","journal-title":"Intensive Care Med"},{"key":"R34-20260521","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/MAT.0000000000000160","article-title":"Extracorporeal membrane oxygenation use has increased by 433% in adults in the United States from 2006 to 2011.","volume":"61","author":"Sauer","year":"2015","journal-title":"ASAIO J"},{"key":"R35-20260521","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMra1208707","article-title":"Ventilator-induced lung injury.","volume":"369","author":"Slutsky","year":"2013","journal-title":"N Engl J Med"},{"key":"R36-20260521","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.athoracsur.2016.11.056","article-title":"Awake extracorporeal membrane oxygenation as bridge to lung transplantation: a 9-year experience.","volume":"104","author":"Biscotti","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"R37-20260521","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/PCC.0000000000000317","article-title":"Association of bleeding and thrombosis with outcome in extracorporeal life support.","volume":"16","author":"Dalton","year":"2015","journal-title":"Pediatr Crit Care Med"},{"key":"R38-20260521","doi-asserted-by":"crossref","first-page":"e0198392","DOI":"10.1371\/journal.pone.0198392","article-title":"Life span of different extracorporeal membrane systems for severe respiratory failure in the clinical practice.","volume":"13","author":"Philipp","year":"2018","journal-title":"PLoS One"},{"key":"R39-20260521","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.3390\/jcm11175147","article-title":"Anticoagulation strategies during extracorporeal membrane oxygenation: a narrative review.","volume":"11","author":"Rajsic","year":"2022","journal-title":"J Clin Med"},{"key":"R40-20260521","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00003088-198611060-00005","article-title":"Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.","volume":"11","author":"Holford","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"R41-20260521","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/aor.13116","article-title":"Meta-analysis of time in therapeutic range in continuous-flow left ventricular assist device patients receiving warfarin.","volume":"42","author":"Martinez","year":"2018","journal-title":"Artif Organs"},{"key":"R42-20260521","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.healun.2025.04.012","article-title":"Low-dose apixaban in HeartMate 3 LVAD patients, interim analysis of the ApixiVAD trial, a randomized controlled study.","volume":"44","author":"Schnegg","year":"2025","journal-title":"J Heart Lung Transplant"},{"key":"R43-20260521","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12959-020-00252-9","article-title":"Suspected heparin-induced thrombocytopenia in a COVID-19 patient on extracorporeal membrane oxygenation support: a case report.","volume":"18","author":"Phan","year":"2020","journal-title":"Thromb J"},{"key":"R44-20260521","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/aor.12595","article-title":"Preclinical study of anticoagulation regimens in sheep after implantation of CH-VAD blood pump.","volume":"42","author":"Xu","year":"2018","journal-title":"Artif Organs"},{"key":"R45-20260521","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/1746-6148-9-192","article-title":"New aspects on efficient anticoagulation and antiplatelet strategies in sheep.","volume":"9","author":"Weigand","year":"2013","journal-title":"BMC Vet Res"},{"key":"R46-20260521","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.actbio.2019.05.019","article-title":"Zwitterionic poly-carboxybetaine coating reduces artificial lung thrombosis in sheep and rabbits.","volume":"92","author":"Ukita","year":"2019","journal-title":"Acta Biomater"},{"key":"R47-20260521","doi-asserted-by":"crossref","first-page":"120778","DOI":"10.1016\/j.biomaterials.2021.120778","article-title":"Combination of polycarboxybetaine coating and factor XII inhibitor reduces clot formation while preserving normal tissue coagulation during extracorporeal life support.","volume":"272","author":"Naito","year":"2021","journal-title":"Biomaterials"},{"key":"R48-20260521","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"R49-20260521","first-page":"530","article-title":"Andexanet Alfa (Andexxa((R> for the reversal of direct oral anticoagulants.","volume":"44","author":"Momin","year":"2019","journal-title":"P T"},{"key":"R50-20260521","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/phar.1882","article-title":"Evaluation of altered drug pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation.","volume":"37","author":"Ha","year":"2017","journal-title":"Pharmacotherapy"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:00:36Z","timestamp":1779382836000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005617","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}